BROOKE KEMPF: Open Payments
NPI 1316257645 · TERRE HAUTE, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$366,634 in 506 payments from 11 companies in 2025. Trend: 2023 $242,768 · 2024 $269,734 · 2025 $366,634
Speaker / faculty: $221,883Travel & lodging: $49,066Consulting: $44,038Honoraria: $41,250Food & beverage: $10,286Education: $111
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 84 | $88,440 |
| Janssen Pharmaceuticals, Inc | 87 | $68,867 |
| Alkermes, Inc. | 125 | $63,652 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 91 | $60,016 |
| Axsome Therapeutics, Inc. | 67 | $41,403 |
| E.R. Squibb & Sons, L.L.C. | 29 | $30,070 |
| Luye Pharma (USA) Ltd. | 12 | $10,633 |
| Neurocrine BioSciences, Inc. | 4 | $1,763 |
| Janssen Scientific Affairs, LLC | 3 | $1,580 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $167 |
Products named: CAPLYTA, AUSTEDO XR, LYBALVI, Auvelity, INVEGA SUSTENNA, SPRAVATO, UZEDY, ARISTADA.
Industry payments across IN — which companies pay providers there.
